Loading
institutionsInstitution
Mayo Clinic
Consistently the top-ranked US hospital overall, with strong proton therapy and the first US carbon-ion centre under construction.
Overview
Mayo Clinic, headquartered in Rochester, Minnesota, is consistently the top-ranked US hospital overall and holds NCI comprehensive designation through the Mayo Clinic Comprehensive Cancer Center, which spans Rochester, Phoenix and Jacksonville; it sits fifth in the Newsweek/Statista oncology ranking. Its cancer strengths are multiple myeloma, lymphoma and individualised medicine, with proton therapy and the first US carbon-ion facility under construction in Jacksonville. OnCo links it to the Atlas pathology model built with Aignostics and Charité, to liver transplantation for cancer, to senescence and JAK-STAT pathway work, and to people including S. Vincent Rajkumar, Shaji K. Kumar and Matthew P. Goetz. Whether carbon-ion therapy earns its cost against protons is the open question its new centre will help answer. The Arizona and Florida campuses have their own OnCo pages.
Location
Rochester, MN, US
Type
hospital
Website
Newsweek 2026 oncology rank
#5
NCI designation
comprehensive
OnCo score
#9 · 136 points (55 Newsweek + 15 NCI + 66 from 33 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Mayo Clinic, including child institutions. 4,572 works · 48,202 citations · 60% open access · 13% clinical trials · 3% reviews.
Oncology works per year
8602022
9612023
9602024
1,0102025
7812026
Most works
- Tanios Bekaii‐Saab143 works
- Yi Lin141 works
- Qian Shi90 works
- Saad S. Kenderian89 works
- Kathryn J. Ruddy84 works
- Frederick Lundry Locke82 works
- Yucai Wang78 works
- Mohamed A. Kharfan‐Dabaja74 works
- Tina J. Hieken73 works
- Javier L Munoz71 works
Most cited
- Carbon-ion therapy (Jacksonville)
- Myeloma
- Proton therapy
A. Oliver Sartor
Professor of Medical Oncology and Urology, Mayo Clinic
Prostate cancerRadioligand therapyPSMA-targeted therapy
Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.
Cheryl L. Willman
Executive Director, Mayo Clinic Comprehensive Cancer Center
Leukaemia genomicsCancer center leadershipHealth disparities
Cheryl Willman is a leukaemia genomics pioneer who leads Mayo Clinic's cancer centre across its three sites.
Evanthia Galanis
Group Chair, Alliance for Clinical Trials in Oncology; Professor of Oncology, Mayo Clinic
Neuro-oncologyOncolytic virusesCooperative group trials
Evanthia Galanis is a brain tumour specialist who chairs one of the largest US clinical trial networks.
Jan C. Buckner
Medical oncologist, Mayo Clinic
Low-grade gliomaNeuro-oncologyCooperative-group trials
Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma.
Keith C. Bible
Medical oncologist, Mayo Clinic
Anaplastic thyroid cancerAdvanced thyroid cancerClinical guidelines
Mayo Clinic oncologist who chaired the American Thyroid Association guidelines for anaplastic thyroid cancer, one of the fastest-growing human cancers.
Mark R. Litzow
Professor of Medicine, Mayo Clinic; Chair, ECOG-ACRIN Leukemia Committee; Study Chair, E1910
Acute lymphoblastic leukaemiaImmunotherapyTransplant
Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.
Matthew P. Goetz
Professor of Oncology and Pharmacology; Co-leader, Women's Cancer Program, Mayo Clinic
Breast cancerPharmacogenomicsCDK4/6 inhibitors
Breast oncologist who led MONARCH 3 and studies how genetics shapes response to endocrine therapy.
Paul D. Brown
Radiation oncologist, Mayo Clinic
Brain metastasesStereotactic radiosurgeryCognitive outcomes of radiotherapy
Mayo Clinic radiation oncologist whose trials showed that focused radiosurgery preserves thinking and memory better than whole-brain radiotherapy for brain metastases, and that sparing the hippocampus reduces cognitive harm when whole-brain treatment is needed.
S. Vincent Rajkumar
Professor of Medicine, Division of Hematology, Mayo Clinic
Multiple myelomaPlasma cell disordersDrug pricing
Myeloma expert who wrote the diagnostic criteria the field uses and a persistent critic of drug prices.
Shaji K. Kumar
Professor of Medicine; Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo Clinic
Multiple myelomaClinical trialsMRD
Myeloma trialist who led venetoclax and quadruplet studies and helped define MRD response criteria.
Stephen A. Boorjian
Chair of Urology, Mayo Clinic
Bladder cancerIntravesical therapyUrological surgery outcomes
Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG.
Stephen J. Russell
Molecular medicine researcher, Mayo Clinic, Rochester; also affiliated with Vyriad, Rochester
Oncolytic virotherapyEngineered measles virusMyeloma
Stephen Russell built the engineered measles viruses used against cancer and reported the case in which one intravenous dose put a patient's myeloma into complete remission.
Tanios Bekaii-Saab
Professor of Medicine; Leader, GI Cancer Program, Mayo Clinic Arizona
Gastrointestinal oncologyColorectal cancerBiliary cancer
GI oncologist behind trials of KRAS, HER2, and FGFR-directed therapy in colorectal and bile duct cancer.
observationalJAMA 2024178 citations
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
The evidence behind the stage I de-escalation statement on the triple-negative page: an ordinary haematoxylin and eosin slide identifies a fifth of patients whose outcome without chemotherapy matches treated cohorts. A prospective trial of chemotherapy omission is the missing step.
observationalJCO Precision Oncology 201970 citations
Circulating tumor DNA profiling of advanced biliary tract cancers
Biliary tumours are often diagnosed on tiny biopsies or brushings, so a blood-based panel that detects HER2 amplification and other targets in half of patients is a practical route to testing, with tissue confirmation where the blood is uninformative.
observationalJAMA 2018changed practice463 citations
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
Family history misses most carriers, so the NCCN and ASCO guidelines moved to testing every patient; each carrier found is a family that can be offered surveillance and a patient who may be eligible for platinum and PARP inhibition.
observationalGastroenterology 2018307 citations
Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes
A scoring tool that needs no new test and can run in primary care records; it turns the 1 percent of Chari's cohort into a 3.6 percent group in whom imaging or a blood test becomes defensible.
observationalJNCI: Journal of the National Cancer Institute 2018227 citations
Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing
It defines the gene list a TNBC germline panel should report on and shows the same genes apply in African American women, the population with the highest TNBC incidence.
observationalJournal of Clinical Oncology 2017280 citations
Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer
It stops a BRAF-mutant report being read as one uniform outlook, and it separates the class II and III mutations, which signal differently and are not covered by the encorafenib plus cetuximab label, from V600E.
observationalJournal of Clinical Oncology 2015changed practice492 citations
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer
This cohort underpins the guideline shift to germline BRCA1/2 testing for all TNBC patients regardless of age or family history, and it is the prevalence figure the corpus uses for germline BRCA1 in TNBC.
meta analysisJAMA 2012changed practice405 citations
Identification of Lynch syndrome among patients with colorectal cancer
It is the evidence behind universal mismatch repair testing of every colorectal cancer, which is now standard in most guidelines and which, as a by-product, identifies everyone eligible for immunotherapy.
Similar pages
- InstitutionTaipei Veterans General Hospital
Shares Hitachi (particle therapy), Carbon-ion therapy, Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS).
- InstitutionCharité Universitätsmedizin Berlin
Shares Aignostics, Atlas (Aignostics, Mayo Clinic, Charité), Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Proton therapy machines: cyclotrons, synchrotrons and single-room systems.
- Key paperRussell 2014: a measles virus given into the vein put one patient's myeloma into complete remission
Shares Evanthia Galanis, Stephen J. Russell, Multiple myeloma.
- TechnologyCarbon-ion synchrotrons and facilities
Shares Hitachi (particle therapy), Carbon-ion therapy, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
- InstitutionNational Cancer Centre Singapore
Shares Hitachi (particle therapy), Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, Biliary tract cancer (cholangiocarcinoma).
- TermMRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)
Shares S. Vincent Rajkumar, Shaji K. Kumar, Multiple myeloma.
- InstitutionHokkaido University Hospital
Shares Hitachi (particle therapy), Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, Hepatocellular carcinoma.
- IdeaBlood-based pancreatic cancer detection in new-onset diabetes
Shares Probability of pancreatic cancer following diabetes: a population-based study, Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
cancers
technologies
companies
institutions
pathways
trials
roadmaps
Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance questionTriple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem
ideas
people
key papers
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic CancerCirculating tumor DNA profiling of advanced biliary tract cancersIdentification of Lynch syndrome among patients with colorectal cancerInherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancerModel to Determine Risk of Pancreatic Cancer in Patients With New-Onset DiabetesNon-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancerProbability of pancreatic cancer following diabetes: a population-based studyTriple-negative breast cancer risk genes identified by multigene hereditary cancer panel testingTumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer